NCT06733922 - ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS | Biotech Hunter

Enrollment

224

Participants

Timeline

Start Date

November 27, 2024

Primary Completion Date

November 22, 2027

Study Completion Date

November 30, 2027

Conditions

Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions

DEVICE

ETNATM-ProgMS

To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.

Trial Locations (9)

T2N 4N1

RECRUITING

Novartis Investigative Site, Calgary

T3M 1M4

RECRUITING

Novartis Investigative Site, Calgary

V6T 2A1

RECRUITING

Novartis Investigative Site, Vancouver

B3R 1V9

RECRUITING

Novartis Investigative Site, Halifax

B1P 1P3

RECRUITING

Novartis Investigative Site, Sydney

K1H 8L6

RECRUITING

Novartis Investigative Site, Ottawa

H1K 3V9

RECRUITING

Novartis Investigative Site, Montreal

H4A 3T2

RECRUITING

Novartis Investigative Site, Montreal

G1W 4R4

RECRUITING

Novartis Investigative Site, Québec